We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
Turnover
43.75%
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+75.12%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$96.8M
AUM Growth
+$25.1M
(+35%)
Cap. Flow
-$7.48M
Cap. Flow
% of AUM
-7.73%
Top 10 Holdings %
Top 10 Hldgs %
75.97%
Holding
36
New
8
Increased
5
Reduced
13
Closed
8
Avg Time Held
1
year
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amylyx Pharmaceuticals
AMLX
|
+$3.14M |
| 2 |
Compass Therapeutics
CMPX
|
+$2.65M |
| 3 |
Ocular Therapeutix
OCUL
|
+$1.8M |
| 4 |
Krystal Biotech
KRYS
|
+$1.58M |
| 5 |
Bright Minds Biosciences
DRUG
|
+$1.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Soleno Therapeutics
SLNO
|
+$5.31M |
| 2 |
Trevi Therapeutics
TRVI
|
+$2.7M |
| 3 |
Cidara Therapeutics
CDTX
|
+$2.43M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$2.38M |
| 5 |
BridgeBio Oncology
BBOT
|
+$1.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Miscellaneous | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Ocular Therapeutix
OCUL
$1.58B
| $13.6M | 14.08% |
1,165,206
+150,266
| +15% | +$1.8M |
2023 Q4
7 quarters
|
|
|
2
DELISTED
Cidara Therapeutics
CDTX
| $13.6M | 14.01% |
141,529
-38,040
| -21% | -$2.43M |
2024 Q4
3 quarters
|
|
3
DELISTED
Tourmaline Bio
TRML
| $12.8M | 13.27% |
268,451
-15,231
| -5% | -$422K |
2023 Q4
7 quarters
|
|
4
Whitehawk Therapeutics
WHWK
$169M
| $6.48M | 6.7% |
3,410,402
| – | – |
2021 Q3
16 quarters
|
|
5
Insmed
INSM
$21.4B
| $5.56M | 5.74% |
38,592
+1,522
| +4% | +$186K |
2023 Q4
7 quarters
|
|
|
6
Bright Minds Biosciences
DRUG
$500M
| $5.15M | 5.32% |
84,875
+36,401
| +75% | +$1.41M |
2024 Q4
3 quarters
|
|
7
argenx
ARGX
$51.5B
| $4.7M | 4.86% |
6,379
-323
| -5% | -$213K |
2024 Q2
5 quarters
|
|
|
8
Amylyx Pharmaceuticals
AMLX
$3.39B
| $4.53M | 4.68% |
+333,258
| New | +$3.14M |
2025 Q3
0 quarters
|
|
9
DELISTED
Terns Pharmaceuticals
TERN
| $3.78M | 3.9% |
502,797
+38,933
| +8% | +$249K |
2022 Q3
12 quarters
|
|
10
Jazz Pharmaceuticals
JAZZ
$13.6B
| $3.31M | 3.42% |
25,114
-1,169
| -4% | -$140K |
2025 Q1
2 quarters
|
|
|
11
Compass Therapeutics
CMPX
$158M
| $2.94M | 3.04% |
+840,090
| New | +$2.65M |
2025 Q3
0 quarters
|
|
12
Praxis Precision Medicines
PRAX
$6.67B
| $2.64M | 2.72% |
49,751
-24,336
| -33% | -$1.18M |
2023 Q2
9 quarters
|
|
13
Surrozen
SRZN
$279M
| $2.3M | 2.38% |
178,415
+8,415
| +5% | +$88.2K |
2025 Q1
2 quarters
|
|
|
14
Ascendis Pharma A/S
ASND
$14.9B
| $1.95M | 2.01% |
9,792
-12,784
| -57% | -$2.38M |
2024 Q3
4 quarters
|
|
|
15
Krystal Biotech
KRYS
$9.79B
| $1.87M | 1.93% |
+10,573
| New | +$1.58M |
2025 Q3
0 quarters
|
|
16
Oculis Holding
OCS
$442M
| $1.79M | 1.85% |
101,777
-4,941
| -5% | -$87.6K |
2025 Q1
2 quarters
|
|
17
Taysha Gene Therapies
TSHA
$1.14B
| $1.49M | 1.54% |
454,827
-30,842
| -6% | -$87.3K |
2025 Q2
1 quarter
|
|
18
Cogent Biosciences
COGT
$4.88B
| $1.48M | 1.53% |
+102,907
| New | +$1.22M |
2025 Q3
0 quarters
|
|
19
Zymeworks
ZYME
$1.78B
| $1.37M | 1.41% |
80,143
-3,512
| -4% | -$50.3K |
2024 Q4
3 quarters
|
|
20
Verastem
VSTM
$698M
| $1.27M | 1.31% |
143,446
-6,968
| -5% | -$51.9K |
2025 Q1
2 quarters
|
|
21
Dianthus Therapeutics
DNTH
$4.18B
| $984K | 1.02% |
+25,000
| New | +$639K |
2025 Q3
0 quarters
|
|
22
United Therapeutics
UTHR
$23.2B
| $963K | 0.99% |
+2,296
| New | +$772K |
2025 Q3
0 quarters
|
|
23
Inhibrx
INBX
$1.25B
| $552K | 0.57% |
+16,377
| New | +$403K |
2025 Q3
0 quarters
|
|
24
Fulcrum Therapeutics
FULC
$280M
| $526K | 0.54% |
57,141
-2,509
| -4% | -$18.2K |
2025 Q2
1 quarter
|
|
25
LB Pharmaceuticals
LBRX
$1.1B
| $474K | 0.49% |
+30,000
| New | +$476K |
2025 Q3
0 quarters
|
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q3 2025 Portfolio in Review
As of Q3 2025, Acuta Capital Partners held 36 positions worth $96.8M, up 35% from $71.6M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Acuta Capital Partners withdrew a net $7.48M in Q3 2025, closing 8 positions and reducing 13 holdings. Its most notable exit was Soleno Therapeutics, an estimated $5.31M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Acuta Capital Partners opened a new position in Amylyx Pharmaceuticals worth $4.53M.
- Acuta Capital Partners's largest Q3 2025 buy was Amylyx Pharmaceuticals: 333,258 shares worth $4.53M.
- Acuta Capital Partners added most to Ocular Therapeutix in Q3 2025, an estimated $1.8M increase.
- Acuta Capital Partners's biggest Q3 2025 reduction was Cidara Therapeutics, cutting an estimated $2.43M.
- Acuta Capital Partners fully exited Soleno Therapeutics in Q3 2025, selling an estimated $5.31M.
- Acuta Capital Partners's ten largest holdings make up 76% of its $96.8M portfolio in Q3 2025.
- Acuta Capital Partners opened 8 new positions and closed 8 in Q3 2025.
- Acuta Capital Partners's portfolio value rose 35% quarter-over-quarter to $96.8M.
Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.